Participants' characteristics, sputum microbiology and antibiotics administered at baseline
| Demographics | |
| Age years | 29.3±10.4 |
| Height m | 1.68±0.09 |
| Body mass index kg·m−2 | 21.9±3.7 |
| Spirometry# | |
| Absolute FEV1 L | 1.70±0.70 |
| FEV1 % pred | 47.2±16.9 |
| Absolute forced vital capacity L | 2.79±1.03 |
| Forced vital capacity % pred | 65.4±19.2 |
| Maintenance therapies | |
| Nebulised colomycin | 38 (63) |
| Nebulised tobramycin | 6 (10) |
| Nebulised DNAse | 36 (60) |
| Nebulised hypertonic saline | 21 (35) |
| Oral corticosteroids | 11 (18) |
| Oral azithromycin | 49 (82) |
| Hospital microbiology results | |
| Pseudomonas aeruginosa alone | 42 (70) |
| Pseudomonas aeruginosa co-infection | |
| MSSA | 5 (8) |
| MRSA and Haemophilus influenzae | 1 (2) |
| MRSA | 1 (2) |
| Candida albicans | 4 (7) |
| Pseudomonas aeruginosa not isolated | |
| MRSA alone | 2 (3) |
| MSSA alone | 1 (2) |
| MSSA and Aspergillus fumigatus | 1 (2) |
| Respiratory commensals only | 3 (5) |
| Intravenous antibiotic administered | |
| Tobramycin | 32 (53) |
| Ceftazidime | 29 (48) |
| Colomycin | 24 (40) |
| Meropenem | 24 (40) |
| Aztreonam | 7 (12) |
| Piperacillin/tazobactam | 5 (8) |
| Other¶ | 5 (8) |
Data are presented as mean±sd or n (%). FEV1: forced expiratory volume in 1 s; MSSA: methicillin-sensitive Staphylococcus aureus; MRSA: methicillin-resistant S. aureus. #: n=58; ¶: other antibiotics consisted of intravenous flucloxacillin (n=2), septrin (n=1), linezolid (n=1) and ofloxacillin (n=1).